Gina Mauro currently serves as Vice President of Content at MJH Life Sciences, overseeing OncLive®, Oncology Nursing News®, and Medical World News®. Gina joined the company in 2015 and has held various positions on OncLive and Oncology Nursing News. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com
Bi-weekly Teclistamab Dosing Receives FDA Approval for Relapsed/Refractory Multiple Myeloma
February 21st 2024A supplemental Biologics License Application for teclistamab-cqyv (Tecvayli) has been approved by the FDA at a reduced dose of 1.5 mg/kg every 2 weeks for the treatment of patients with relapsed/refractory multiple myeloma who have maintained a complete response or greater for at least 6 months.
FDA Approves Eflornithine for Children, Adults With High-Risk Neuroblastoma
December 14th 2023Eflornithine (Iwilfin) received FDA approval to reduce the risk for relapse in pediatric and adult patients with high-risk neuroblastoma, making it the first therapy to reduce risk for relapse in children with the disease.
Neoadjuvant/Adjuvant Pembrolizumab Regimen Continues to Show EFS Benefit in High-Risk Early TNBC
December 10th 2023The 5-year event-free survival rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab, compared with 72.3% in those who received placebo/chemotherapy plus placebo.
Apalutamide Does Not Impact Patient-Reported Side Effect Burden, HRQOL in mCSPC
May 2nd 2022The addition of apalutamide to androgen deprivation therapy does not lead to a significant patient-reported side effect burden nor a reduction in health-related quality of life in patients with metastatic castration-sensitive prostate cancer.
2-Year Follow-Up Showcases Sotorasib Benefit in KRAS G12C+ NSCLC
April 15th 2022Longer follow-up data from the phase 1/2 CodeBreaK 100 trial show that patients with KRAS G12C–mutant non–small cell lung cancer experienced improved prolonged overall survival and encouraging response rates with sotorasib.